Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Climb Bio, Inc. (CLYM : NSDQ)

• Company Description    Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $12.84 Daily Weekly Monthly 20 Day Moving Average: 1,466,952 shares Shares Outstanding: 57.26 (millions) Market Capitalization: $735.26 (millions) Beta: 0.07 52 Week High: $14.42 52 Week Low: $1.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.42% 0.68% 12 Week 44.59% 40.63% Year To Date 221.00% 194.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 William Street Suite 145 - Wellesley Hills,MA 02481 USA ph: 866-857-2596 fax: - investorrelations@climbbio.com http://www.eliemtx.com

• General Corporate Information    Officers Aoife Brennan - President; Chief Executive Officer and Director Douglas E. Williams - Chairman Susan Altschuller - Chief Financial Officer Cindy J. Driscoll - Senior Vice President Kimberlee C. Drapkin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28658R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 57.26 Most Recent Split Date: (:1) Beta: 0.07 Market Capitalization: $735.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.14 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.48% vs. Previous Quarter: 23.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -31.45 12/31/25 - -33.41 ROA 06/30/26 - - 03/31/26 - -30.39 12/31/25 - -32.21 Current Ratio 06/30/26 - - 03/31/26 - 27.86 12/31/25 - 15.16 Quick Ratio 06/30/26 - - 03/31/26 - 27.86 12/31/25 - 15.16 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 3.10 12/31/25 - 3.36 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©